tickertape
← runs

PFE

PFIZER INCeval run
10-K for period ending 2025-12-31gpt-6-luna@none · prompt v4$0.00114.9sfiling on sec.gov ↗

figures

fieldvaluestatement rowprintedSEC
Total revenue$62.6BR6 Total revenues62,579 millions$62.6B ✓
Operating income-not printed on this statement--
Net income attributable to the company$7.8BR21 Net income attributable to Pfizer Inc. common shareholders7,771 millions$7.8B ✓
Diluted EPS$1.36R29 Net income attributable to Pfizer Inc. common shareholders1.36$1.36 ✓
Cash and cash equivalents$1.1BR3 Cash and cash equivalents1,142 millions$1.1B ✓
Total assets$208.2BR16 Total assets208,160 millions$208.2B ✓
Total liabilities$121.4BR31 Total liabilities121,385 millions$121.4B ✓
Total shareholders' equity attributable to the company$86.5BR38 Total Pfizer Inc. shareholders’ equity86,476 millions$86.5B ✓
Net cash from operating activities$11.7BR21 Net cash provided by/(used in) operating activities11,704 millions$11.7B ✓
Net cash from investing activities-$1.4BR32 Net cash provided by/(used in) investing activities(1,351) millions-$1.4B ✓
Net cash from financing activities-$10.3BR41 Net cash provided by/(used in) financing activities(10,304) millions-$10.3B ✓

checks

  • assets = liabilities + equity · total assets equals total liabilities and equity
  • equity excludes minority interests · totalEquity excludes noncontrolling interests
  • net income is before preferred dividends · net income is not the after-preferred-dividends line
  • diluted EPS is for total net income · diluted EPS is for total net income
  • net income excludes minority interests · netIncome excludes noncontrolling interests
  • cash flows tie to the change in cash · operating + investing + financing = 49000000, but the printed net change in cash is 91000000

management's claims

Found 3 claims, none about a company-wide figure the statements can confirm.

trace

  1. 0locator (code)0.25s
    {
  "tables": 264,
  "exhibits": [],
  "documents": 1
}
    {
  "income": {
    "rows": 32,
    "scale": 1000000,
    "score": 51.25,
    "heading": "Consolidated Statements of Operations Pfizer Inc. and Subsidiary Companies",
    "tableIndex": 111,
    "runnerUpScore": 25.25
  },
  "balance": {
    "rows": 42,
    "scale": 1000000,
    "score": 54.5,
    "heading": "Consolidated Balance Sheets Pfizer Inc. and Subsidiary Companies",
    "tableIndex": 115,
    "runnerUpScore": 26.75
  },
  "cashflow": {
    "rows": 48,
    "scale": 1000000,
    "score": 55,
    "heading": "Consolidated Statements of Cash Flows Pfizer Inc. and Subsidiary Companies",
    "tableIndex": 119,
    "runnerUpScore": 16
  }
}
  2. 1cash flow agent1.62s · 1801 tokens · $0.0002
    {
  "rows": 48,
  "retryHint": null,
  "tableIndex": 119
}
    {
  "figures": [
    {
      "note": "This is the operating activities section total, including changes in assets and liabilities.",
      "field": "operatingCashFlow",
      "scale": 1000000,
      "value": 11704000000,
      "printed": "11,704",
      "rowIndex": 21,
      "rowLabel": "Net cash provided by/(used in) operating activities",
      "priorValue": 12744000000,
      "agentPrinted": "11,704",
      "failedChecks": [],
      "priorPrinted": "12,744",
      "groundingMismatch": false
    },
    {
      "note": "This is the investing activities section total.",
      "field": "investingCashFlow",
      "scale": 1000000,
      "value": -1351000000,
      "printed": "(1,351)",
      "rowIndex": 32,
      "rowLabel": "Net cash provided by/(used in) investing activities",
      "priorValue": 2652000000,
      "agentPrinted": "(1,351)",
      "failedChecks": [],
      "priorPrinted": "2,652",
      "groundingMismatch": false
    },
    {
      "note": "This is the financing activities section total.",
      "field": "financingCashFlow",
      "scale": 1000000,
      "value": -10304000000,
      "printed": "(10,304)",
      "rowIndex": 41,
      "rowLabel": "Net cash provided by/(used in) financing activities",
      "priorValue": -17140000000,
      "agentPrinted": "(10,304)",
      "failedChecks": [],
      "priorPrinted": "(17,140)",
      "groundingMismatch": false
    }
  ],
  "statement": "cashflow",
  "tableIndex": 119,
  "priorColumn": 1,
  "currentColumn": 0
}
  3. 2income statement agent1.67s · 1695 tokens · $0.0002
    {
  "rows": 32,
  "retryHint": null,
  "tableIndex": 111
}
    {
  "figures": [
    {
      "note": "This is the company-wide total revenues line.",
      "field": "revenue",
      "scale": 1000000,
      "value": 62579000000,
      "printed": "62,579",
      "rowIndex": 6,
      "rowLabel": "Total revenues",
      "priorValue": 63627000000,
      "agentPrinted": "62,579",
      "failedChecks": [],
      "priorPrinted": "63,627",
      "groundingMismatch": false
    },
    {
      "note": "The statement does not print an operating income or equivalent line.",
      "field": "operatingIncome",
      "scale": 1000000,
      "value": null,
      "printed": null,
      "rowIndex": null,
      "rowLabel": null,
      "priorValue": null,
      "agentPrinted": null,
      "failedChecks": [],
      "priorPrinted": null,
      "groundingMismatch": false
    },
    {
      "note": "This is net income attributable to Pfizer Inc. common shareholders, excluding noncontrolling interests.",
      "field": "netIncome",
      "scale": 1000000,
      "value": 7771000000,
      "printed": "7,771",
      "rowIndex": 21,
      "rowLabel": "Net income attributable to Pfizer Inc. common shareholders",
      "priorValue": 8031000000,
      "agentPrinted": "7,771",
      "failedChecks": [],
      "priorPrinted": "8,031",
      "groundingMismatch": false
    },
    {
      "note": "This is diluted EPS for total net income attributable to Pfizer common shareholders.",
      "field": "epsDiluted",
      "scale": 1,
      "value": 1.36,
      "printed": "1.36",
      "rowIndex": 29,
      "rowLabel": "Net income attributable to Pfizer Inc. common shareholders",
      "priorValue": 1.41,
      "agentPrinted": "1.36",
      "failedChecks": [],
      "priorPrinted": "1.41",
      "groundingMismatch": false
    }
  ],
  "statement": "income",
  "tableIndex": 111,
  "priorColumn": 1,
  "currentColumn": 0
}
  4. 3balance sheet agent1.72s · 1555 tokens · $0.0002
    {
  "rows": 42,
  "retryHint": null,
  "tableIndex": 115
}
    {
  "figures": [
    {
      "note": "This is the cash and cash equivalents line for the current period.",
      "field": "cash",
      "scale": 1000000,
      "value": 1142000000,
      "printed": "1,142",
      "rowIndex": 3,
      "rowLabel": "Cash and cash equivalents",
      "priorValue": 1043000000,
      "agentPrinted": "1,142",
      "failedChecks": [],
      "priorPrinted": "1,043",
      "groundingMismatch": false
    },
    {
      "note": "This row explicitly prints total assets.",
      "field": "totalAssets",
      "scale": 1000000,
      "value": 208160000000,
      "printed": "208,160",
      "rowIndex": 16,
      "rowLabel": "Total assets",
      "priorValue": 213396000000,
      "agentPrinted": "208,160",
      "failedChecks": [],
      "priorPrinted": "213,396",
      "groundingMismatch": false
    },
    {
      "note": "This is the separate total liabilities line, not liabilities and equity.",
      "field": "totalLiabilities",
      "scale": 1000000,
      "value": 121385000000,
      "printed": "121,385",
      "rowIndex": 31,
      "rowLabel": "Total liabilities",
      "priorValue": 124899000000,
      "agentPrinted": "121,385",
      "failedChecks": [],
      "priorPrinted": "124,899",
      "groundingMismatch": false
    },
    {
      "note": "This is Pfizer Inc. shareholders’ equity, excluding noncontrolling interests.",
      "field": "totalEquity",
      "scale": 1000000,
      "value": 86476000000,
      "printed": "86,476",
      "rowIndex": 38,
      "rowLabel": "Total Pfizer Inc. shareholders’ equity",
      "priorValue": 88203000000,
      "agentPrinted": "86,476",
      "failedChecks": [],
      "priorPrinted": "88,203",
      "groundingMismatch": false
    }
  ],
  "statement": "balance",
  "tableIndex": 115,
  "priorColumn": 1,
  "currentColumn": 0
}
  5. 4reconciler (code)0.00s
    null
    [
  {
    "name": "balance_identity",
    "detail": "total assets equals total liabilities and equity",
    "fields": [
      "totalAssets"
    ],
    "passed": true,
    "skipped": false,
    "statement": "balance"
  },
  {
    "name": "totalEquity_attribution",
    "detail": "totalEquity excludes noncontrolling interests",
    "fields": [
      "totalEquity"
    ],
    "passed": true,
    "skipped": false,
    "statement": "balance"
  },
  {
    "name": "netIncome_before_preferred",
    "detail": "net income is not the after-preferred-dividends line",
    "fields": [
      "netIncome"
    ],
    "passed": true,
    "skipped": false,
    "statement": "income"
  },
  {
    "name": "epsDiluted_total",
    "detail": "diluted EPS is for total net income",
    "fields": [
      "epsDiluted"
    ],
    "passed": true,
    "skipped": false,
    "statement": "income"
  },
  {
    "name": "netIncome_attribution",
    "detail": "netIncome excludes noncontrolling interests",
    "fields": [
      "netIncome"
    ],
    "passed": true,
    "skipped": false,
    "statement": "income"
  },
  {
    "name": "cash_flow_tie",
    "detail": "operating + investing + financing = 49000000, but the printed net change in cash is 91000000",
    "fields": [
      "operatingCashFlow",
      "investingCashFlow",
      "financingCashFlow"
    ],
    "passed": false,
    "skipped": false,
    "statement": "cashflow"
  }
]
  6. 5MD&A claims agent2.36s · 3326 tokens · $0.0005
    null
    [
  {
    "kind": "amount_change",
    "field": "revenue",
    "quote": "Total revenues decreased $1.0 billion, or 2%, to $62.6 billion in 2025 from $63.6 billion in 2024, reflecting an operational decrease of $1.3 billion, or 2%, partially offset by a favorable impact of foreign exchange of $247 million.",
    "scope": "consolidated",
    "actual": null,
    "reason": "Total revenue: the sentence is about a region, segment or adjusted measure",
    "claimed": null,
    "verdict": "not_checked",
    "asWritten": "$1.0 billion",
    "tolerance": null,
    "quoteVerified": true
  },
  {
    "kind": "percent_change",
    "field": "revenue",
    "quote": "Total revenues decreased $1.0 billion, or 2%, to $62.6 billion in 2025 from $63.6 billion in 2024, reflecting an operational decrease of $1.3 billion, or 2%, partially offset by a favorable impact of foreign exchange of $247 million.",
    "scope": "consolidated",
    "actual": null,
    "reason": "Total revenue: the sentence is about a region, segment or adjusted measure",
    "claimed": null,
    "verdict": "not_checked",
    "asWritten": "2%",
    "tolerance": null,
    "quoteVerified": true
  },
  {
    "kind": "current_value",
    "field": "revenue",
    "quote": "Total revenues decreased $1.0 billion, or 2%, to $62.6 billion in 2025 from $63.6 billion in 2024, reflecting an operational decrease of $1.3 billion, or 2%, partially offset by a favorable impact of foreign exchange of $247 million.",
    "scope": "consolidated",
    "actual": null,
    "reason": "Total revenue: the sentence is about a region, segment or adjusted measure",
    "claimed": null,
    "verdict": "not_checked",
    "asWritten": "$62.6 billion",
    "tolerance": null,
    "quoteVerified": true
  }
]

Income statement

table #111 · current period is figure column 1
0Year Ended December 31,
1(MILLIONS, EXCEPT PER SHARE DATA)202520242023
2Revenues:
3Product revenues51,66353,81650,914
4Alliance revenues9,2668,3887,582
5Royalty revenues1,6501,4231,058
6Total revenues← Total revenue62,57963,62759,553
7Costs and expenses:
8Cost of sales(a), (b)16,06717,85124,954
9Selling, informational and administrative expenses(a)13,79414,73014,771
10Research and development expenses(a)10,43710,82210,679
11Acquired in-process research and development expenses1,613108194
12Amortization of intangible assets4,8745,2864,733
13Restructuring charges and certain acquisition-related costs1,5502,4192,943
14Other (income)/deductions--net6,7244,388222
15Income from continuing operations before provision/(benefit) for taxes on income7,5208,0231,058
16Provision/(benefit) for taxes on income(266)(28)(1,115)
17Income from continuing operations7,7878,0512,172
18Discontinued operations--net of tax2511(15)
19Net income before allocation to noncontrolling interests7,8128,0622,158
20Less: Net income attributable to noncontrolling interests413139
21Net income attributable to Pfizer Inc. common shareholders← Net income attributable to the company7,7718,0312,119
22Earnings per common share--basic:
23Income from continuing operations attributable to Pfizer Inc. common shareholders1.371.420.38
24Discontinued operations--net of tax---
25Net income attributable to Pfizer Inc. common shareholders1.371.420.38
26Earnings per common share--diluted:
27Income from continuing operations attributable to Pfizer Inc. common shareholders1.361.410.37
28Discontinued operations--net of tax---
29Net income attributable to Pfizer Inc. common shareholders← Diluted EPS1.361.410.37
30Weighted-average shares--basic5,6835,6645,643
31Weighted-average shares--diluted5,7135,7005,709

Balance sheet

table #115 · current period is figure column 1
0As of December 31,
1(MILLIONS, EXCEPT PER SHARE DATA)20252024
2Assets
3Cash and cash equivalents← Cash and cash equivalents1,1421,043
4Short-term investments12,45419,434
5Trade accounts receivable, net of allowance for doubtful accounts: 2025-$427; 2024-$43811,87411,463
6Inventories10,65410,851
7Current tax assets3,9673,314
8Other current assets2,8084,253
9Total current assets42,89850,358
10Long-term investments1,6212,228
11Property, plant and equipment, net19,31718,393
12Identifiable intangible assets, net53,73155,411
13Goodwill71,26468,527
14Noncurrent deferred tax assets and other noncurrent tax assets9,6998,662
15Other noncurrent assets9,6319,817
16Total assets← Total assets208,160213,396
17Liabilities and Equity
18Short-term borrowings, including current portion of long-term debt: 2025-$2,997; 2024-$3,7473,1546,946
19Trade accounts payable5,2405,633
20Dividends payable2,4452,437
21Income taxes payable3,1032,910
22Accrued compensation and related items3,6103,838
23Deferred revenues7841,511
24Other current liabilities18,64819,720
25Total current liabilities36,98442,995
26Long-term debt61,64157,405
27Pension and postretirement benefit obligations2,0412,115
28Noncurrent deferred tax liabilities2,4012,122
29Other taxes payable3,5916,112
30Other noncurrent liabilities14,72514,150
31Total liabilities← Total liabilities121,385124,899
32Commitments and Contingencies
33Common stock, $0.05 par value; 12,000 shares authorized; issued: 2025-9,621; 2024-9,593481480
34Additional paid-in capital94,46993,603
35Treasury stock, shares at cost: 2025-3,935; 2024-3,926(115,015)(114,763)
36Retained earnings114,610116,725
37Accumulated other comprehensive loss(8,069)(7,842)
38Total Pfizer Inc. shareholders’ equity← Total shareholders' equity attributable to the company86,47688,203
39Equity attributable to noncontrolling interests299294
40Total equity86,77588,497
41Total liabilities and equity208,160213,396

Cash flow statement

table #119 · current period is figure column 1
0Year Ended December 31,
1(MILLIONS)202520242023
2Operating Activities
3Net income before allocation to noncontrolling interests7,8128,0622,158
4Discontinued operations-net of tax2511(15)
5Net income from continuing operations before allocation to noncontrolling interests7,7878,0512,172
6Adjustments to reconcile net income from continuing operations before allocation to noncontrolling interests to net cash provided by/(used in) operating activities:
7Depreciation and amortization6,5927,0136,290
8Asset write-offs and impairments5,2704,2423,408
9Deferred taxes(2,133)(2,102)(3,442)
10Share-based compensation expense799877525
11Benefit plan contributions in excess of expense/income(786)(12)(787)
12Inventory write-offs and related charges associated with COVID-19 products(a)--6,199
13Other adjustments, net(470)(2,260)(3,492)
14Other changes in assets and liabilities, net of acquisitions and divestitures:
15Trade accounts receivable(263)(109)347
16Inventories(a)561(854)(1,169)
17Other assets1,2893,380(663)
18Trade accounts payable(469)(1,023)(300)
19Other liabilities(b)(3,667)(3,115)595
20Other tax accounts, net(2,805)(1,345)(982)
21Net cash provided by/(used in) operating activities← Net cash from operating activities11,70412,7448,700
22Investing Activities
23Purchases of property, plant and equipment(2,629)(2,909)(3,907)
24Purchases of short-term investments(14,356)(10,133)(30,974)
25Proceeds from redemptions/sales of short-term investments17,9594,12839,264
26Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less(2,675)3,1365,174
27Purchases of long-term investments(294)(180)(204)
28Proceeds from redemptions/sales of long-term investments1,0951,5701,979
29Proceeds from partial sales of investment in Haleon(c)6,3117,040-
30Acquisitions of businesses, net of cash acquired(6,927)-(43,430)
31Other investing activities, net1652(179)
32Net cash provided by/(used in) investing activities← Net cash from investing activities(1,351)2,652(32,278)
33Financing Activities
34Proceeds from short-term borrowings-8,9074,525
35Payments on short-term borrowings(2,199)(11,226)(3)
36Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less(796)(2,590)3,161
37Proceeds from issuance of long-term debt9,678-30,831
38Payments on long-term debt(6,757)(2,250)(2,569)
39Cash dividends paid(9,771)(9,512)(9,247)
40Other financing activities, net(458)(469)(631)
41Net cash provided by/(used in) financing activities← Net cash from financing activities(10,304)(17,140)26,066
42Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents41(66)(40)
43Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents91(1,810)2,448
44Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period1,1072,917468
45Cash and cash equivalents and restricted cash and cash equivalents, at end of period1,1971,1072,917
46- Continued -
47Pfizer Inc.2025 Form 10-K56